-
Capital, M&A & Industry Strategy1 month agoRetension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede
Eli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals are the latest biotechs to set out plans to go public this year.
-
Capital, M&A & Industry Strategy1 month agoElectra dips after pricing upsized IPO, bucking trend: Public Equity Report
BIOCENTURY | FINANCEELECTRA DIPS AFTER PRICING UPSIZED IPO, BUCKING TREND: PUBLIC EQUITY REPORTPlus: Two more companies line up PIPEs to accompany mergers; Tyra’s follow-on; and more
-
Capital, M&A & Industry Strategy1 month agoThis week in charts: GSK’s China deals, the $300M IPO club and selling the news
The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer look at an industry-leading partnership...
-
Capital, M&A & Industry Strategy1 month agoSTAT+: Pharmalittle: We’re reading about licensing deals with China, making drugs in space, and more
The U.S. is working on rules for investing in China that would likely preserve pharma's ability to strike most licensing deals for Chinese drugs
-
Capital, M&A & Industry Strategy1 month agoA national security priority: BIO pushes PAHPA reauthorization in 2026
For decades, Congress has passed legislation to protect Americans from public health emergencies, ranging from national security threats to disease outbreaks and natural disasters, […] The...
-
Capital, M&A & Industry Strategy1 month agoWhich biotechs have raised new VC financing this week?
This week's biggest biotech venture financings include sizeable rounds for Sling Therapeutics, Circle Pharma, and RegCell.
-
Capital, M&A & Industry Strategy1 month ago
Inflammation biotech Electra charges up with $350M from upsized IPO
Electra Therapeutics is the latest biotech to overshoot its own IPO expectations this year, with the inflammation-focused company bringing in $350 million from this morning’s Nasdaq...
-
Capital, M&A & Industry Strategy1 month agoElectra amasses $350M in biotech’s latest big IPO
Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new...
-
Capital, M&A & Industry Strategy1 month agoScale as strategy: Blackstone’s Galakatos on funding the hardest mile
BIOCENTURY | FINANCESCALE AS STRATEGY: BLACKSTONE’S GALAKATOS ON FUNDING THE HARDEST MILENick Galakatos joins The BioCentury Show to discuss the path from Clarus to a $6.3B...
-
Capital, M&A & Industry Strategy1 month agoWith Tepezza challenge in late-stage study, Sling draws $123M series C: Venture Report
BIOCENTURY | FINANCEWITH TEPEZZA CHALLENGE IN LATE-STAGE STUDY, SLING DRAWS $123M SERIES C: VENTURE REPORTPlus: Circle draws $92.5M round after introducing second development candidate; and more
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
